Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV001023582 | SCV001185482 | uncertain significance | Hereditary cancer-predisposing syndrome | 2019-12-13 | criteria provided, single submitter | clinical testing | The p.Q1709R variant (also known as c.5126A>G), located in coding exon 33 of the ATM gene, results from an A to G substitution at nucleotide position 5126. The glutamine at codon 1709 is replaced by arginine, an amino acid with highly similar properties. This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV000122858 | SCV000166116 | uncertain significance | Ataxia-telangiectasia syndrome | 2014-06-11 | no assertion criteria provided | clinical testing | The interpretation for this sequence variant was made by Invitae based on the ACMG guidelines. |